Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
631528
Reference Type
Book/Book Chapter
Title
Michael addition-elimination reactions: Roles in toxicity and potential new therapeutic applications
Author(s)
Elfarra, AA; Krause, RJ
Year
2008
Publisher
Springer
Location
New York, NY
Book Title
Advances in Bioactivation Research
Page Numbers
57-68
DOI
10.1007/978-0-387-77300-1_3
Abstract
Activated olefins of the type XCH = CHY, where Y is an electron- withdrawing group and X is a good leaving group, can undergo nucleophilic vinylic substitution reactions by a single-step or a multistep addition-limination mechanism, depending on the chemical structure of the olefin and the reaction conditions. While nucleophilic vinylic substitution reactions have been extensively characterized and described in the chemical literature (Koch and Kielbania 1970; Kahn and Hehre 1986; Hackett et al. 1990; Rappoport 1992; Galli, Gentili and Rappoport 1994), only recently have these reactions been recognized to occur at physiological conditions and have been implicated in biological activity. The purpose of this chapter is to review recent experimental evidence that documents occurrence of Michael addition-limination reactions in intact mammalian cells, both in vitro and in vivo. Evidence implicating these reactions in the mechanisms of nephrotoxicity and renal carcinogenicity of the halogenated hydrocarbons, trichloroethylene, and tetrachloroethylene will also be discussed. Finally, adaptation of Michael addition-limination reactions to design new anticancer prodrugs that can undergo bioactivation by biological thiols, such as glutathione (GSH) and glutathione S-transferases (GST), to release the cytoxic drug 6-mercaptopurine (6-MP) or 6-thioguanine (6-TG) will also be described. Furthermore, data demonstrating the effectiveness of this prodrug approach in increasing the efficacy of 6-MP and 6-TG against tumor cells while decreasing the known side-effects of these drugs on the bone marrow and small intestine will be reviewed.
Keywords
6-mercaptopurine-- antineoplastic-drug,enzyme inhibitor-drug; 6-thioguanine--antineoplastic-drug; Acids; activated olefins--biological activity; Animals; Biochemistry and Molecular Biophysics; Biosis 07/14/08 to 03/03/09; cancer chemotherapy--laboratory techniques; Chordates; elimination reaction; glutathione S-transferase {GST}; glutathione {GSH}; Literature Review; Mammalia--Vertebrata,Chordata,Animalia; mammalian cell line (Mammalia); Mammals; methods; Michael addition; Nonhuman Mammals; Nonhuman Vertebrates; nucleophilic vinylic substitution; pathology; Peptides; pharmacology; physiological condition; renal carcinogenicity; Tetrachloroethylene; tetrachloroethylene--toxin,nephrotoxin; therapeutic application; therapy; toxicity; Toxicology; Trichloroethylene; trichloroethylene--toxin,nephrotoxin; Vertebrates
Editor(s)
AA Elfarra
Tags
IRIS
•
Tetrachloroethylene (Perc) (Final, 2012)
All References
•
Trichloroethylene (TCE) (Final, 2011)
OPPT REs
•
OPPT_Perchloroethylene (Perc)_C. Engineering
Total – title/abstract screening
Off topic
•
OPPT_Perchloroethylene (Perc)_D. Exposure
Total – title/abstract screening
Off topic
•
OPPT_Perchloroethylene (Perc)_E. Fate
Total – title/abstract screening
Off topic
•
OPPT_Perchloroethylene (Perc)_F. Human Health
Total – title/abstract screening
Off topic
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity